Evaluation of a new oral beta2-adrenoceptor stimulant bronchodilator, terbutaline.
A double-blind crossover comparison was made of the effect of orally administered terbutaline (a new adrenergic drug with major action on beta2-receptors), ephedrine, and placebo in 15 patients with obstructive airways disease. Serial determination of ventilatory tests, arterial gas tensions, arterial blood pressure, ECG, blood chemistries, and urinalysis were made before and after administration of the tested drug. Terbutaline (5 mg) was found to be an effective bronchodilator with minimal side effects and an earlier onset and longer duration of action than ephedrine (25 mg).
D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000402:Airway Obstruction / Q000188:drug therapy*; D001249:Asthma / Q000188:drug therapy; D001794:Blood Pressure / Q000187:drug effects; D001993:Bronchodilator Agents; D002245:Carbon Dioxide / Q000097:blood; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004562:Electrocardiography; D004809:Ephedrine / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005540:Forced Expiratory Flow Rates; D005541:Forced Expiratory Volume; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D010919:Placebos; D012119:Respiration / Q000187:drug effects*; D013268:Stimulation, Chemical; D013726:Terbutaline / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014797:Vital Capacity
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D010919:Placebos; D002245:Carbon Dioxide; D004809:Ephedrine; D013726:Terbutaline; D010100:Oxygen